Study details
Enrolling now
Dapagliflozin Trial
Northwestern University
NCT IDNCT05719714ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1/2
Target enrollment
60
Study length
about 2.7 years
Ages
18–85
Locations
1 site in IL
About this study
Researchers are testing if dapagliflozin, a medication for diabetes, can change the way your heart and lungs work in people with chronic kidney disease. The trial will also look at changes in substances created when our bodies break down food, drugs, or its own tissues.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Dapagliflozin 10 MG [Farxiga]
PhasePhase 1/Phase 2
DrugDapagliflozin 10 MG [Farxiga]
Routeoral
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
dapagliflozin, antidiabetic (Dapagliflozin (SGLT2 inhibitor))
Drug routes
oral (Oral Tablet)
Body systems
Renal, Cardiology / Heart